Learn more about investing in Jointechlabs, Inc.

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
We don’t spam. Our Privacy Policy and Cookie Policy apply. The site is protected by reCAPTCHA.
Jointechlabs, Inc.
Jointechlabs, Inc.
Pioneering access to high-quality fat grafts, fat-derived stem cells, and cell therapies
CONTACT COMPANY
INVESTOR INQUIRIES
Human Health Therapeutics IBSF06 2018 Seed Human Health 100 United States
* Data source: Crunchbase
Founded
2013
Employees*
2-10
Funding to Date*
$250K
Website
jointechlabs.com
* Data source: Crunchbase
Nishit Pancholi, MD, COO
The use of autologous body fats makes the procedure safer and better, and ours is the only solution that can process the fat at point of care at half the price.
Global regenerative medicine market will reach $50B by 2025

Jointechlabs Inc. is an emerging leader in point-of-care regenerative and rejuvenation medicine therapies. We have patented, portable medicine products that enable personalized therapies. Our medical device allows doctors, clinics, and hospitals to provide safe- and cost-effective non-surgical regenerative and healing treatments for patients.

Team
Nathan Katz
CEO & Co-Founder
Nishit Pancholi
CDO & Co-Founder
Felix Pustilnik
COO & Co-Founder
Company News
BioWorld | August 27, 2020
FDA gives green light to Jointechlabs’ MiniTC device

Regenerative therapies startup Jointechlabs Inc. has won the U.S. FDA’s nod for its MiniTC point-of-care fat tissue processing device. The 510(k)-cleared product is designed to extract microfat for use in grafts for a variety of indications, including medical aesthetics, plastic surgery, orthobiologics and wound healing.